3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis

Lori Ferrins, Raphael Steve Rahmani, Melissa L Sykes, Amy J Jones, Vicky M Avery, Eliott Teston, Basmah Almohaywi, JieXiang Yin, Jason Smith, Hyland Chris, Karen Louise White, Eileen Ryan, Michael Campbell, Susan Ann Charman, Marcel Kaiser, Jonathan Bayldon Baell

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)


A whole organism high-throughput screen of approximately 87,000 compounds against Trypanosoma brucei brucei led to the recent discovery of several novel compound classes with low micromolar activity against this organism and without appreciable cytotoxicity to mammalian cells. Herein we report a structure activity relationship (SAR) investigation around one of these hit classes, the 3-(oxazolo[4,5-b] pyridin-2-yl)anilides. Sharp SAR is revealed, with our most active compound (5) exhibiting an IC50 of 91 nM against the human pathogenic strain T.b. rhodesiense and being more than 700 times less toxic towards the L6 mammalian cell line. Physicochemical properties are attractive for many compounds in this series. For the most potent representatives, we show that solubility and metabolic stability are key parameters to target during future optimisation.
Original languageEnglish
Pages (from-to)450 - 465
Number of pages16
JournalEuropean Journal of Medicinal Chemistry
Publication statusPublished - 2013

Cite this